Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 2
2012 6
2013 6
2014 8
2015 8
2016 17
2017 17
2018 14
2019 23
2020 28
2021 21
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 33067340

121 results
Results by year
Filters applied: . Clear all
Page 1
18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients.
Binderup T, Knigge U, Johnbeck CB, Loft A, Berthelsen AK, Oturai P, Mortensen J, Federspiel B, Langer SW, Kjaer A. Binderup T, et al. J Nucl Med. 2020 Oct 16:jnumed.120.244798. doi: 10.2967/jnumed.120.244798. Online ahead of print. J Nucl Med. 2020. PMID: 33067340
Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
Zemczak A, Kołodziej M, Gut P, Królicki L, Kos-Kudła B, Kamiński G, Ruchała M, Pawlak D, Kunikowska J. Zemczak A, et al. Endokrynol Pol. 2020;71(3):240-248. doi: 10.5603/EP.a2020.0014. Epub 2020 Apr 15. Endokrynol Pol. 2020. PMID: 32293704 Free article.
Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias.
Karfis I, Marin G, Levillain H, Drisis S, Muteganya R, Critchi G, Taraji-Schiltz L, Guix CA, Shaza L, Elbachiri M, Mans L, Machiels G, Hendlisz A, Flamen P. Karfis I, et al. Oncotarget. 2020 Feb 11;11(6):589-599. doi: 10.18632/oncotarget.27460. eCollection 2020 Feb 11. Oncotarget. 2020. PMID: 32110279 Free PMC article.
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
Werner RA, Ilhan H, Lehner S, Papp L, Zsótér N, Schatka I, Muegge DO, Javadi MS, Higuchi T, Buck AK, Bartenstein P, Bengel F, Essler M, Lapa C, Bundschuh RA. Werner RA, et al. Mol Imaging Biol. 2019 Jun;21(3):582-590. doi: 10.1007/s11307-018-1252-5. Mol Imaging Biol. 2019. PMID: 30014345
121 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page